Guideline

KDIGO 2025 clinical practice guideline for the management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)

Read time: 1 mins

Last updated: 1st Oct 2025

Source: Kidney Disease: Improving Global Outcomes (KDIGO)

Availability: Free full text

Status: Current

KDIGO 2025 clinical practice guideline for the management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)

The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) represents a focused update of Chapter 2: Immunoglobulin A Nephropathy (IgAN)/Immunoglobulin A Vasculitis (IgAV) from the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The aim is to assist healthcare providers caring for people with IgAN or IgAV. The update takes into consideration evidence from randomized controlled trials published through April 2023 and updated in August 2024. As in 2021, this guideline provides guidance related to diagnosis, prognosis, treatment, and special situations. Based on the new evidence, this update is mostly related to the guidance relevant to IgAN. Development of this guideline followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the certainty of the evidence and the strength of recommendations following the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach. Limitations of the evidence are discussed, and areas of future research are also presented.

Read full Guideline